What is Curiox Biosystems?
Curiox Biosystems operates at the intersection of surface chemistry and advanced engineering, specializing in the development and commercialization of innovative assay platforms. The company's core value proposition lies in its ability to enhance the precision and efficiency of bioassays through automation and miniaturization. By streamlining these workflows, Curiox enables researchers to achieve higher throughput and more reliable data, which are critical requirements for modern drug discovery and clinical diagnostics. As a leader in bioinstrumentation, the firm leverages its deep technical expertise to solve complex challenges in life sciences, effectively bridging the gap between laboratory research and commercial-scale application.
How much funding has Curiox Biosystems raised?
Curiox Biosystems has raised a total of $33.2M across 3 funding rounds:
Series A
$3.2M
Series B
$15M
Series C
$15M
Series A (2010): $3.2M with participation from Zicom Group
Series B (2019): $15M led by QUAD Investment, SV Investment, HB Investment, KB Investment, IMM Investment, and DAYLI Investment
Series C (2022): $15M supported by Quad Investment Management, KB Investment, and Luha Private Equity
Key Investors in Curiox Biosystems
Quad Investment Management
Quad Investment Management is a specialized investment firm focused on identifying high-growth opportunities within the technology and life sciences sectors.
KB Investment
KB Investment is a venture capital and private equity firm. It offers investment in venture companies that offer innovative technology, service, and entrepreneurship. The company was established in 1990 and is headquartered in Seoul, South Korea.
SV Investment
SV Investment is a prominent venture capital firm that provides strategic financial support to companies demonstrating significant potential for technological disruption.
What's next for Curiox Biosystems?
With the successful closure of its latest financing round, Curiox Biosystems is well-positioned to accelerate its commercial expansion and deepen its R&D capabilities. The strategic focus will likely shift toward scaling the adoption of its automated platforms in key international markets, particularly as the demand for high-fidelity diagnostic tools continues to rise. By leveraging its robust capital base, the company is expected to enhance its product portfolio, potentially integrating new analytical features that further simplify complex biological workflows. As the life sciences industry moves toward more automated and data-driven methodologies, Curiox's commitment to innovation ensures it remains at the forefront of the bioinstrumentation landscape, ready to capitalize on emerging opportunities in personalized medicine and high-throughput screening.
See full Curiox Biosystems company page
